ES2188985T3 - Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. - Google Patents

Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.

Info

Publication number
ES2188985T3
ES2188985T3 ES97942899T ES97942899T ES2188985T3 ES 2188985 T3 ES2188985 T3 ES 2188985T3 ES 97942899 T ES97942899 T ES 97942899T ES 97942899 T ES97942899 T ES 97942899T ES 2188985 T3 ES2188985 T3 ES 2188985T3
Authority
ES
Spain
Prior art keywords
enantiomeric
nucleic acids
evolution
selection
molecula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97942899T
Other languages
English (en)
Inventor
Jens Peter Furste
Rolf Bald
Volker A Erdmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2188985T3 publication Critical patent/ES2188985T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ecology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Tea And Coffee (AREA)

Abstract

SE EXPONE UN PROCEDIMIENTO PARA IDENTIFICAR Y PRODUCIR ACIDOS L-NUCLEICOS, QUE INTERACCIONAN CON UNA MOLECULA-BLANCO QUE TIENE UNA CONFIGURACION NATURAL, ASI COMO LOS ACIDOS LNUCLEICOS OBTENIDOS POR ESTE PROCEDIMIENTO. SE EXPONEN IGUALMENTE EL USO DE ACIDOS D-NUCLEICOS QUE SE FIJAN A LA ANTIPODA OPTICA DE LA MOLECULA-BLANCO COMO MATRIZ PARA PRODUCIR ACIDOS L-NUCLEICOS CON SECUENCIA IDENTICA, Y MEDICAMENTOS Y CONJUNTOS QUE CONTIENEN EL ACIDO L-NUCLEICO EXPUESTO.
ES97942899T 1996-08-30 1997-08-29 Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. Expired - Lifetime ES2188985T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96113953 1996-08-30

Publications (1)

Publication Number Publication Date
ES2188985T3 true ES2188985T3 (es) 2003-07-01

Family

ID=8223148

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97942899T Expired - Lifetime ES2188985T3 (es) 1996-08-30 1997-08-29 Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.

Country Status (8)

Country Link
US (1) US6605713B1 (es)
EP (1) EP0934331B1 (es)
JP (1) JP2001504448A (es)
AT (1) ATE228529T1 (es)
AU (1) AU743469C (es)
DE (1) DE59708838D1 (es)
ES (1) ES2188985T3 (es)
WO (1) WO1998008856A2 (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2799465B1 (fr) * 1999-10-12 2004-02-13 Centre Nat Rech Scient Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
AU2001269039A1 (en) * 2000-05-26 2001-12-11 Noxxon Pharma Ag Immobilized nucleic acids and uses thereof
DE10122862A1 (de) * 2001-05-11 2002-11-21 Noxxon Pharma Ag GnRH bindende Nukleinsäure
DE10122847A1 (de) * 2001-05-11 2002-11-21 Noxxon Pharma Ag Enterotoxin B bindende Nukleinsäure
DK1264603T3 (da) * 2001-06-10 2010-04-26 Noxxon Pharma Ag Anvendelse af L-polynukleotider til in vivo-billeddannelse
EP1288309A1 (de) * 2001-08-30 2003-03-05 Noxxon Pharma AG Verfahren zur Markierung von L-Nukleinsäuren
EP1306382A1 (de) * 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
DK1438321T5 (da) * 2001-10-26 2011-02-21 Noxxon Pharma Ag Modificeret L-nukleinsyre
US20030219422A1 (en) * 2001-11-15 2003-11-27 Noxxon Pharma Ag Allosteric ribozymes and uses thereof
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10211558A1 (de) * 2002-03-15 2003-10-09 Noxxon Pharma Ag Neue Formen RNAi
AU2003233243A1 (en) * 2002-05-06 2003-11-17 Noxxon Pharma Ag Method for amplifying nucleic acids
US20060099178A1 (en) 2002-05-27 2006-05-11 Holm Per S Novel use of adenoviruses and nucleic acids coding therefor
EP1386972A1 (en) * 2002-08-01 2004-02-04 Noxxon Pharma AG Method and apparatus for designing a nucleic acid having a desired property
EP1393742A1 (en) 2002-08-14 2004-03-03 atugen AG Use of protein kinase N beta
DK1536827T3 (da) 2002-08-14 2009-04-20 Silence Therapeutics Ag Anvendelse af proteinkinase N-beta
ES2314238T3 (es) 2002-10-08 2009-03-16 Fresenius Kabi Deutschland Gmbh Conjugados de oligosacaridos farmaceuticamente activos.
EP2314604A3 (en) 2002-10-15 2011-05-25 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
WO2004035615A2 (en) 2002-10-18 2004-04-29 Atugen Ag Factor involved in metastasis and uses thereof
EP2287314A1 (en) 2003-03-04 2011-02-23 Intercell AG Streptococcus pyogenes antigens
ATE449177T1 (de) 2003-03-31 2009-12-15 Intercell Ag Staphylococcus epidermidis antigene
JP2007525157A (ja) 2003-04-15 2007-09-06 インターツェル・アクチェンゲゼルシャフト 肺炎連鎖球菌抗原
CN101864431A (zh) 2003-05-07 2010-10-20 英特塞尔股份公司 无乳链球菌抗原ⅰ和ⅱ
WO2004106367A2 (en) 2003-05-30 2004-12-09 Intercell Ag Enterococcus antigens
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
JP2007511211A (ja) 2003-11-14 2007-05-10 ホルム，ペル・ゾンネ アデノウイルスおよびそれをコードしている核酸の新たな使用
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
EP2992902A1 (en) 2004-12-27 2016-03-09 Silence Therapeutics GmbH Lipid complexes coated with peg and their uses
US20060199207A1 (en) * 2005-02-24 2006-09-07 Matysiak Stefan M Self-assembly of molecules using combinatorial hybridization
KR101418367B1 (ko) * 2005-05-04 2014-07-25 녹손 파르마 아게 에이치엠지에이-결합 핵산
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
BRPI0620806B8 (pt) 2005-12-30 2022-07-05 Evonik Roehm Gmbh complexo e composição compreendendo um peptídeo e uma molécula carga, e uso da referida composição
JP4984990B2 (ja) * 2006-03-28 2012-07-25 富士通株式会社 機能性分子の製造方法
ES2549728T3 (es) 2006-04-20 2015-11-02 Silence Therapeutics Gmbh Formulaciones de lipoplexo para la administración específica al endotelio vascular
CA2652280C (en) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
CN101490253A (zh) 2006-07-21 2009-07-22 赛伦斯治疗公司 用于抑制蛋白激酶3表达的方法
CA2661224A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
EP1913955A1 (en) 2006-10-19 2008-04-23 Gerhard, Markus Novel method for treating H.pylori infections
WO2008119571A2 (en) * 2007-01-03 2008-10-09 Novo Nordisk A/S Nucleic acid myostatin antagonist aptamers obtained by (mirror- image) selex
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
EP2152731A2 (en) * 2007-05-02 2010-02-17 Intercell AG Klebsiella antigens
AU2008265218A1 (en) 2007-06-18 2008-12-24 Intercell Ag Chlamydia antigens
WO2009033027A2 (en) 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain
EP2045326A1 (en) * 2007-10-05 2009-04-08 Bayer CropScience AG Method for identifying the interaction partner of an active agent
EP3424525A1 (en) 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Vaccine nanotechnology
WO2009053691A1 (en) 2007-10-22 2009-04-30 Pronota Nv Method of selecting aptamers
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
EP2393504B1 (de) * 2009-02-06 2013-06-05 Freie Universität Berlin Ein l-ribozym enthaltende pharmazeutische zusammensetzung zur behandlung von nebenwirkungen durch gabe von spiegelmeren
WO2010092176A2 (en) 2009-02-13 2010-08-19 Intercell Ag Nontypable haemophilus influenzae antigens
DE102009058769A1 (de) 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung
WO2011098262A2 (en) 2010-02-09 2011-08-18 Universität Bremen P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth
WO2011150258A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
WO2012022496A2 (en) 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
WO2012090150A2 (en) 2010-12-27 2012-07-05 Compugen Ltd New cell-penetrating peptides and uses thereof
DE102010056610A1 (de) * 2010-12-31 2012-07-05 Volker A. Erdmann Pharmazeutische Zusammensetzung enthaltend L-DNA
CN103339258A (zh) 2011-01-10 2013-10-02 诺松制药股份公司 具有对于靶分子的结合亲和力的核酸分子及产生所述核酸分子的方法
US20140243391A1 (en) 2011-07-22 2014-08-28 Centre National De La Recherche Scientifique Phospholipid-detergent conjugates and uses thereof
WO2013034579A1 (en) 2011-09-05 2013-03-14 Rheinische Friedrich-Wilhelms-Universität Bonn Biosynthetic gene cluster for the production of peptide/protein analogues
US20140248294A1 (en) 2011-10-05 2014-09-04 University Of Bremen Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
ES2967272T3 (es) 2011-11-30 2024-04-29 Bullerdiek Joern Expresión de miARNs en tejido placentario
WO2013170960A1 (en) 2012-05-16 2013-11-21 Silence Therapeutics Ag Use of vegfr1 as a biomarker for pkn3 inhibitor administration
EP2850192B1 (en) * 2012-05-16 2023-11-01 APTARION biotech AG Enzymatic synthesis of l-nucleic acids
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
JP2015532306A (ja) 2012-10-15 2015-11-09 チューリッヒ大学 癌治療のための二重特異性ｈｅｒ２リガンド
EP2759602A1 (en) 2013-01-25 2014-07-30 Charité - Universitätsmedizin Berlin Non-invasive prenatal genetic diagnostic methods
EP2837939A1 (en) 2013-08-13 2015-02-18 Technische Universität München Method for the detection of H.pylori infection
EP3065744B1 (en) 2013-11-04 2021-04-21 Noxxon Pharma AG A ccl2 antagonist for use in treating proteinuria
CN105916992A (zh) * 2013-11-20 2016-08-31 诺松制药股份公司 通过酶合成l-核酸
WO2015082080A1 (en) 2013-12-05 2015-06-11 Silence Therapeutics Gmbh Means for lung specific delivery
AU2015205753A1 (en) 2014-01-10 2016-07-21 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating HER2 positive tumors
EP3501531A1 (en) 2014-01-29 2019-06-26 Université de Strasbourg New target for diabetes treatment and prevention
ES2796090T3 (es) 2014-02-10 2020-11-25 Inst Curie Uso de moduladores MCOLN-1 para regular la migración celular
CN112546230A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
WO2016004876A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
EP3000483A1 (en) 2014-09-29 2016-03-30 Charité - Universitätsmedizin Berlin Means and methods for the diagnosis and treatment of neurodegenerative diseases
WO2016196218A1 (en) 2015-05-31 2016-12-08 Curegenix Corporation Combination compositions for immunotherapy
EP3264092A1 (en) 2016-07-01 2018-01-03 Centogene AG Use of lyso-gb1 as druggable target
EP3315125A1 (en) 2016-10-31 2018-05-02 Silence Therapeutics (London) Ltd Lipid nanoparticle formulation
BR112019012253A2 (pt) 2016-12-16 2020-01-28 Centre Hospitalier Univ Bordeaux inibidores de mmp9 e usos dos mesmos na prevenção ou tratamento de um transtorno de despigmentação
EP3421485A1 (en) 2017-06-30 2019-01-02 Université de Strasbourg Peptides for treatment and prevention of hyperglycaemia
EP3521828A1 (en) 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema
CA3092907A1 (en) 2018-03-05 2019-09-12 Klinikum Rechts Der Isar Der Technischen Universitat Munchen Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor
WO2019193526A1 (en) 2018-04-05 2019-10-10 Tsinghua University Methods of sequencing and producing nucleic acid sequences
BR112021007724A2 (pt) * 2018-11-12 2021-08-10 Aptarion Biotech Ag ácidos nucleicos de ligação à cxcl8
CN214973877U (zh) 2019-08-09 2021-12-03 胡桃钳医疗公司 用于形成治疗性多核苷酸的微流体设备及微流体路径装置
AU2020342594A1 (en) 2019-09-05 2022-03-10 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a CDK4/6 inhibitor and a further therapeutically active agent
EP4076647A1 (en) 2019-12-20 2022-10-26 CureVac AG Lipid nanoparticles for delivery of nucleic acids
EP4395748A1 (en) 2021-09-03 2024-07-10 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780221A (en) * 1995-05-03 1998-07-14 Whitehead Institute For Biomedical Research Identification of enantiomeric ligands
JPH11505527A (ja) * 1995-05-03 1999-05-21 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 鏡像異性体リガンドの同定
GB9609722D0 (en) * 1996-05-09 1996-07-10 Smithkline Beecham Corp Novel method

Also Published As

Publication number Publication date
EP0934331B1 (de) 2002-11-27
ATE228529T1 (de) 2002-12-15
WO1998008856A2 (de) 1998-03-05
EP0934331A2 (de) 1999-08-11
AU4456897A (en) 1998-03-19
US6605713B1 (en) 2003-08-12
DE59708838D1 (de) 2003-01-09
JP2001504448A (ja) 2001-04-03
AU743469B2 (en) 2002-01-24
WO1998008856A3 (de) 1998-05-07
AU743469C (en) 2004-02-12

Similar Documents

Publication Publication Date Title
ES2188985T3 (es) Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.
ES2000015T3 (es) Superficies polimericas modificadas y metodo de preparacion de las mismas.
ES2143529T3 (es) Tela no tejida absorbente mejorada.
ES2145580T3 (es) Metodos y composiciones para analizar moleculas de acido nucleico que emplean tecnicas basadas en el tamaño.
ES2105999T3 (es) Procedimiento para la preparacion industrial de fosfatidilserina.
ES2056115T3 (es) Medios y metodos para mejorar la hibridacion de un acido nucleico.
AR031185A1 (es) Casquillo de empalme interacoplable, de baja perdida, para fibras opticas y un metodo para la fabricacion de este
ES2068202T3 (es) Composicion liquida suavizante para prendas de ropa.
ES2102312A1 (es) Procedimiento para la cristalizacion del iopamidol.
DE3579806D1 (de) Einrichtung zum entblenden von grossflaechigen leuchtmitteln.
ES2001923A6 (es) Procedimiento para preparar 3-amino-dihidro-(1)-benzo(tio)piranos.
ATE458964T1 (de) Universelles system mit optischen fasern zur beleuchtung einer vitrine eines museums
ES2139143T3 (es) Gel micro-mesoporoso y procedimiento para su preparacion.
EA200301144A1 (ru) Микропористые волокна с развитой поверхностью, полученные из полимерных растворов
SE9901306D0 (sv) Improved TIRF chamber
ES2116327T3 (es) Nuevas composiciones amorfas transparentes con una resistencia elevada a los agentes quimicos.
AR008295A1 (es) Celulas inmortalizadas, y metodo para producir y usar dichas celulas para la produccion de virus.
ES493536A0 (es) Procedimiento para revestir una caja catodica que tiene una pluralidad de catodos foraminados con cavidad, con un dia- fragma sintetico.
EA199900842A1 (ru) Модуляторы функции рецепторов, принадлежащих к семейству рецепторов tnf/ngf
ES2062027T3 (es) Nuevos tienopiranos sustituidos como agentes antihipertensores.
AR009819A1 (es) Inhibidores de la proteasa proteinicos estabilizados y sus variantes
EA200000069A1 (ru) Способ получения 4-замещенных-1h-индол-3-глиоксамидов
ES2165551T3 (es) Bacillus sp. ac13 alcalofilo y xilanasa obtenida a partir de dicha especie.
DE60106170D1 (de) Transparente, elastische und selbsttragende Verbindung zur Herstellung von Kerzen und mit dieser Verbindung hergestellte selbsttragende Kerze
ES2083427T3 (es) Procedimiento para fabricar 2-oxindol-1-carboxamidas.